Several CAR-T cells have been developed to target GBM, and a few, including epidermal growth factor receptor (EGFR)-VIII, human epidermal growth factor receptor 2 (HER2), and interleukin (IL)-13Rα2-targeting CAR-T cells, have been applied in clinical trials with promising results in a limited number of patients.29, 30, 31, 32, 33 These mixed results point toward the fact that while CAR-T cell therapy is indeed effective against brain tumors, it does have its own limitations. This evidence concerns the gene IL13RA2 and brain neoplasm.